Biora Therapeutics announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding to test the BioJet platform’s ability to achieve bioavailability through oral delivery of the undisclosed collaborator’s molecules to the small intestine in animal models.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIOR:
- Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
- Biora Therapeutics: FDA clears IND application for BT-600
- Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- BIOR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update